Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 12/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.43 |
| ▸ | NPY1R | P25929 | 8/20 | 0.43 |
| ▸ | NPY2R | P49146 | 6/20 | 0.40 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.39 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30129763 | 0.98 | NPY4R (0.42) | NPY4RNPY5RNPY1RNPY2RQRFPR | |
| SCHEMBL7869393 | 0.92 | NPY4R (0.44) | NPY4RNPY5RNPY1RNPY2RNPBWR1 | |
| SCHEMBL7869385 | 0.92 | NPY4R (0.44) | NPY4RNPY5RNPY1RNPY2RNPBWR1 | |
| SCHEMBL30372279 | 0.91 | QRFPR (0.41) | NPY4RNPY5RNPY1RNPY2RQRFPR | |
| SCHEMBL30373025 | 0.91 | QRFPR (0.41) | NPY4RNPY5RNPY1RNPY2RQRFPR | |
| SCHEMBL29630453 | 0.91 | PTGS1 (0.39) | NPY4RNPY5RNPY1RNPY2RQRFPR | |
| SCHEMBL29591850 | 0.90 | QRFPR (0.39) | NPY4RNPY5RNPY1RNPY2RQRFPR | |
| SCHEMBL30997463 | 0.88 | QRFPR (0.41) | NPY4RNPY5RNPY1RNPY2RQRFPR | |
| SCHEMBL31691754 | 0.87 | NPY4R (0.42) | NPY4RNPY5RNPY1RNPY2RQRFPR | |
| SCHEMBL30372208 | 0.87 | NPY4R (0.42) | NPY4RNPY5RNPY1RNPY2RQRFPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577305-B2 | Multispecific antigen binding proteins capable of binding CD19 and CD3, and use thereof | ITABMED (HK) LIMITED (CN) | 2026-03-17 | — | — | US | disclosed |
| US-12460000-B2 | Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof | ITABMED (HK) LIMITED (CN) | 2025-11-04 | — | — | US | disclosed |
| CN-112867735-B | Bispecific antigen binding proteins and uses thereof | 埃泰美德(香港)有限公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2025087266-A1 | IMMUNOMODULATORY MRNA CASSETTES, AND USES THEREOF | Abogen Biosciences (Shanghai) Co., Ltd. (CN) | 2025-05-01 | — | — | WO | disclosed |
| WO-2025087250-A1 | THERAPEUTIC MRNA CANCER VACCINE TARGETING HPV-ASSOCIATED CANCERS | Abogen Biosciences (Shanghai) Co., Ltd. (CN) | 2025-05-01 | — | — | WO | disclosed |
| WO-2025049345-A1 | ANTI-IL-13 MULTISPECIFIC ANTIBODY CONSTRUCTS AND USES THEREOF | PROTEOLOGIX US INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| CN-113906054-B | Multispecific antigen-binding proteins capable of binding CD19 and CD3 and uses thereof | 埃泰美德(香港)有限公司 | 2024-11-05 | — | — | CN | disclosed |
| CN-118434444-A | MNA-based HPV+ cancer vaccine and uses thereof | 艾博生物科技(上海)有限公司 | 2024-08-02 | — | — | CN | disclosed |
| US-20230192805-A1 | CHIMERIC RECEPTOR POLYPEPTIDES AND USES THEREOF | NANJING LEGEND BIOTECH CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230079150-A1 | METHODS FOR PREVENTION OR TREATMENT OF VIRUS-INDUCED ORGAN INJURY OR FAILURE WITH IL-22 DIMER | Evive Biotechnology (Shanghai) Ltd (CN) | 2023-03-16 | — | — | US | disclosed |
| EP-4103219-A1 | METHODS FOR PREVENTION OR TREATMENT OF VIRUS-INDUCED ORGAN INJURY OR FAILURE WITH IL-22 DIMER | Evive Biotechnology (Shanghai) Ltd (CN) | 2022-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577305-B2 | Multispecific antigen binding proteins capable of binding CD19 and CD3, and use thereof | IGSF11, CD2BP2, CD2 | NPY4R 3259/4885NPY5R 3888/4885NPY1R 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.